Norah Lynn Henry, MD, PhD
Manage Your Profile
About
N. Lynn Henry, MD, PhD is a Professor of Internal Medicine and Associate Director for Community Outreach and Engagement for the Rogel Cancer Center. She was formerly Interim Division Chief and section head for breast oncology in the Division of Hematology/Oncology, associate director of Training, Research, and Education for the Rogel Cancer Center, and Co-Director of the Michigan Breast Oncology Quality Consortium. She is also Co-Chair of the Symptom Management and Quality of Life Committee for the SWOG National Cancer Treatment Network research base. She completed her undergraduate training at Louisiana State University, her doctoral degree in structural biology at Stanford University School of Medicine, and her medical degree at Washington University School of Medicine in St Louis, MO. She then completed her internal medicine residency training at Brigham and Women's Hospital in Boston, MA, followed by hematology/oncology fellowship at the University of Michigan. Dr. Henry cares for patients with all types and stages of breast cancer. Her research is focused on toxicity of therapy for patients with breast cancer, including understanding the mechanisms of development of side effects, identifying which patients are likely to tolerate treatment, and examining interventions to manage toxicity. She has received grant funding from the National Cancer Institute, the American Cancer Society, the Damon Runyon Cancer Research Foundation, the V Foundation, the Hope Foundation for Cancer Research, and the Breast Cancer Research Foundation.
Qualifications
-
Hematology/Oncology FellowshipUniversity of Michigan, United States
2004 - 2007
Clinical Fellowship
-
Internal Medicine ResidencyBrigham and Women's Hospital, Boston, MA, United States
2001 - 2004
Residency
-
MDWashington University School of Medicine, 660 S. Euclid, St Louis, Missouri, 63110, United States
1996 - 2001
-
PhDStanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, United States
1991 - 1996
Center Memberships
-
Center MemberTaubman Institute
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberRogel Cancer Center
-
Center Membere-Health and Artificial Intelligence Initiative
-
Center MemberAI and Digital Health Innovation
-
Center MemberCenter for Global Health Equity
Recent Publications
-
Knoerl R, Jardine J, Chugh R, Fecher LA, Henry NL, Joquico M, Karimi Y, Ploutz-Snyder R, Taylor S, Walling E, Zick S. Support Care Cancer, 2026 Jun 24; 34 (7):Journal ArticleDetermining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivors.
DOI:10.1007/s00520-026-10917-2 PMID: 42337155 -
Henry L. 2026 Jun 28;PresentationEarly Stage Breast Cancer: ASCO Updates
-
Mamounas EP, Tang G, Puhalla SL, Swain SM, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N. Journal of Clinical Oncology, 2026 May 30; 44 (16_suppl): tps650 - tps650.Proceeding / Abstract / PosterA phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.
DOI:10.1200/jco.2026.44.16_suppl.tps650 -
Unger JM, Henry NL, Fisch MJ, Hershman DL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 12143 - 12143.Journal ArticleA risk prediction model for severe, life-threatening, and fatal treatment-related toxicity.
DOI:10.1200/jco.2026.44.16_suppl.12143 -
Henry NL, Darke AK, Unger JM, Schott AF, Kumar P, Mazo-Canola M, Sathe CM, Cabrera-Galeana PA, Kengla AT, Fisch MJ, Hershman DL. Journal of Clinical Oncology, 2026 Jun 1; 44 (16): 521 - 521.Proceeding / Abstract / PosterAssociations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.
DOI:10.1200/JCO.2026.44.16_suppl.521 -
Gunturu KS, Unger JM, Hershman DL, Darke AK, Wei AZ, Hu-Lieskovan S, Walshauser MA, Sochat M, Fisch MJ, Henry NL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 2640 - 2640.Proceeding / Abstract / PosterImmune checkpoint inhibitor (ICI) toxicity in a large prospective cohort of patients with solid tumors: The I-CHECKIT study (SWOG S2013).
DOI:10.1200/jco.2026.44.16_suppl.2640 -
Henry L, Griffith K, Kozar S, Scheu K, Cobain E, Armstrong J, Secor M, Snyder S, Zick S. 2026 Jun 26;Proceeding / Abstract / PosterPhase 2 study of self-acupressure for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
-
Trivedi MS, Unger JM, Hertz DL, Till C, Brannagan T, Reyes S, Schneider BP, Irvin WJ, Hathaway AR, Vander Woude AC, Gudena VK, Cabrera-Galeana PA, Orsted M, LeBlanc M, Fisch MJ, Henry NL, Hershman DL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 12117 - 12117.Proceeding / Abstract / PosterPost-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
DOI:10.1200/jco.2026.44.16_suppl.12117
Featured News & Stories